Effects of atorvastatin on red-blood cell Na+/Li+ countertransport in hyperlipidemic patients with and without hypertension

Abstract

Background: To explore the effect of short-term cholesterol-lowering treatment with atorvastatin on erythrocyte sodium-lithium countertransport (Na+/Li+ CT) activity. Methods: Group A consisted of 30 patients (14 men) with mild essential hypertension (systolic blood pressure (SBP), 140-159 mm Hg and/or diastolic BP, 90-99 mm Hg) and primary hypercholesterolemia low-density lipoprotein (LDL) cholesterol >4.1 mmol/l and triglycerides (TG) <2.8 mmol/l), group B of 30 normotensive patients (16 men) with primary hypercholesterolemia, while 37 (18 men) healthy volunteers comprised the control group. After a 6-week dietary lead-in, all eligible patients were prescribed 20 mg/day of atorvastatin. Anthropometric data, blood-pressure (BP) measurements and determinations of lipid, non-lipid metabolic parameters (including homeostasis model assessment index, (HOMA-IR)) and erythrocyte Na+/Li+ CT activity were collected at baseline and after 12 weeks of treatment. Results: At baseline Na +/Li+ CT activity was significantly higher in group A and B compared with the control group and correlated directly with obesity indices, systolic and diastolic BP, total cholesterol, LDL-cholesterol, TG, apolipoprotein B (apoB), HOMA-IR, uric acid and inversely with high-density lipoprotein (HDL)-cholesterol and apoA1. Systolic and diastolic BP levels, HOMA-IR and Na+/Li+ CT activity were significantly decreased after atorvastatin treatment in both patient groups. The reduction in Na+/Li+ CT activity correlated with baseline Na +/Li+ CT activity and the changes in HOMA-IR values. Conclusions: Short-term treatment with atorvastatin for patients with hypercholesterolemia, and with or without essential hypertension, is associated with a significant reduction in the erythrocyte Na+/Li+ CT activity, BP levels and insulin resistance independent of concomitant changes in lipid parameters. © 2008 American Journal of Hypertension, Ltd.